1. Home
  2. ANTX vs KRRO Comparison

ANTX vs KRRO Comparison

Compare ANTX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

HOLD

Current Price

$4.75

Market Cap

170.6M

Sector

Health Care

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$12.58

Market Cap

150.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTX
KRRO
Founded
2017
2014
Country
United States
United States
Employees
21
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.6M
150.0M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
ANTX
KRRO
Price
$4.75
$12.58
Analyst Decision
Buy
Buy
Analyst Count
1
12
Target Price
$2.00
$34.80
AVG Volume (30 Days)
334.8K
144.5K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
32.56
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$1.00
$5.20
52 Week High
$6.91
$55.89

Technical Indicators

Market Signals
Indicator
ANTX
KRRO
Relative Strength Index (RSI) 70.62 47.56
Support Level $1.06 $12.51
Resistance Level $6.91 $14.76
Average True Range (ATR) 0.36 0.77
MACD 0.13 -0.19
Stochastic Oscillator 81.23 10.05

Price Performance

Historical Comparison
ANTX
KRRO

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: